Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 2:30 p.m. PT in San Francisco, CA. A live audio webcast of the presentation will be available on the “Investors & Media” section of the Company’s website, www.isispharm.com. A replay will be available on the Isis website within 48 hours and will be archived for a limited time. About Isis Pharmaceuticals, Inc. Isis is exploiting its leadership position in RNA-targeted technology to discover and develop novel… Read more
Shares of Isis Pharmaceuticals opened today at $62.52 and are currently trading down at $60.71. ISIS has a 1-year high of $67.12 and a 1-year low of $22.25. The stock’s 50-day moving average is $55.96 and it’s 200-day moving average is $41.84.
On the ratings front, Isis Pharmaceuticals has been the subject of a number of recent research reports. In a report published on December 16, analyst Cory Kasimov from J.P. Morgan assigned a Hold rating to ISIS, with a price target of $65, which represents a slight upside potential from current levels. Separately, on December 10, Piper Jaffray`s Joshua Schimmer assigned a Buy rating to Isis Pharmaceuticals shares.
One research analyst has assigned a Hold rating and 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is 62.52$ which is 7.8% above where the stock opened today.
Isis Pharmaceuticals is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a broad pipeline of first-in-class drugs.